Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
Feature|Articles|September 18, 2025
- Vol.26/No.12
- Volume 26
- Issue 12
Targeted Therapies Drive Demand for Comprehensive Biomarker Testing in NSCLC
Author(s)Ashling Wahner
Fact checked by: Chris Ryan, Tracy Ann Politowicz
Lung cancer experts share the evolution of biomarker testing that has led to advances in patient selection for treatment, as well as challenges that future developments may address.
Advertisement
Advertisement
The non–small cell lung cancer (NSCLC) treatment paradigm has welcomed the addition of numerous targeted therapies over the past several years, prompting a complementary increase in molecular testing rates and innovative tumor sequencing methods. However, persisting barriers to testing, such as tissue insufficiency, emphasize the need for increased diligence through repeat biopsies and improved testing alternatives such as liquid biopsies, according to lung cancer experts interviewed by OncLive®.
Related to this article
RELATIVITY-1093 is comparing nivolumab and relatlimab plus chemotherapy vs pembrolizumab plus chemotherapy in PD-L1–positive nonsquamous NSCLC.
IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Are we ready to “take that fork in the road” and move palliative/supportive care into routine cancer care?
Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Yale experts address borderline resectability, perioperative chemoimmunotherapy, pCR-guided adjuvant therapy, and osimertinib in early-stage NSCLC.
TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions
Faculty at an OncLive Scientific Interchange and Workshop discussed factors that help inform treatment selection in advanced EGFR-mutated NSCLC.
Advertisement
Advertisement